{"entity":{"id":"nct05908409","kind":"trial","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","aka":[],"tldr":"A phase 1/2 trial of IDP-121 in multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by IDP Discovery Pharma S.L., now recruiting.","summary":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies is a phase 1/2 interventional study registered as NCT05908409 by IDP Discovery Pharma S.L., with 37 participants planned, started 2023-06-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: IDP-121.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05908409","url":"https://clinicaltrials.gov/study/NCT05908409"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","dlbcl","non-hodgkin-lymphoma","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05908409","phase":"1/2","setting":"A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)","sponsor":"IDP Discovery Pharma S.L.","enrolled":37,"outcomes":[]},"route":"/trials/nct05908409/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}